Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Non-Hodgkin Lymphoma|Hodgkin Lymphoma
DRUG: Etoposide|DRUG: BCNU|DRUG: AraC|DRUG: Melphalan|PROCEDURE: Peripheral blood stem cell transplantation|BIOLOGICAL: G-CSF|DRUG: Cyclophosphamide|RADIATION: Total Body Irradiation
Progression Free Survival Comparison, Compare progression-free survival (PFS) at 3 years post-transplant for patients who received who received a radiation free preparative regimen to the prior study MT2004-24 where NHL subjects received total body irradiation (TBI) as part of their preparative regimen., 3 years post transplant
Overall Survival, Incidence of survival, 3 years post transplant|Treatment related mortality, Incidence of treatment related mortality, 6 months post transplant|Treatment related mortality, Incidence of treatment related mortality, 1 year post transplant|Secondary malignancies, Cumulative incidence of secondary malignancies, 3 years post transplant|Neutrophil engraftment, Average days to neutrophil engraftment, Day +1 to engraftment|Platelet engraftment, Average days to platelet engraftment, Day +1 to engraftment
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.